Single-Dose, Open-Label Evaluation of TX000045 in Patients with Combined or Isolated Postcapillary Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

The primary objective of this study is to evaluate the effects of a single dose of **TX000045** in patients diagnosed with **combined postcapillary and precapillary pulmonary hypertension (CpcPH)** or **isolated postcapillary pulmonary hypertension (IpcPH)**, in conjunction with **heart failure with preserved ejection fraction (HFpEF)**. This investigation is clinically relevant as it aims to address the therapeutic needs of patients with these complex cardiovascular conditions, potentially improving management strategies and patient outcomes.

The clinical trial involves a total of **15 participants** diagnosed with **combined postcapillary and precapillary pulmonary hypertension** or isolated postcapillary pulmonary hypertension. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, nor are any specific lifestyle considerations such as diet, physical activity, or habits mentioned. The sponsor has not provided detailed information regarding the principal inclusion or exclusion criteria for this trial.

The clinical trial is designed as a **Phase 3** study to evaluate the effects of a single dose of TX000045 in patients diagnosed with **combined postcapillary and precapillary pulmonary hypertension** or **isolated postcapillary pulmonary hypertension**. The trial is structured as an open-label study, meaning that both the researchers and participants are aware of the treatment being administered. The estimated duration of the trial spans from March 1, 2024, to January 31, 2025, with participant recruitment commencing at the start of this period.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment to ensure that participants meet the necessary conditions for inclusion in the study. Following the initial screening, participants will receive the investigational product and will be monitored through scheduled follow-up visits. These visits are designed to assess the safety and efficacy of the treatment, as well as to monitor any adverse events or changes in the participants' health status. The trial will conclude with an end-of-study visit, where final evaluations will be conducted to gather data on the primary and secondary endpoints of the study.

The expected length of participant involvement in the trial is approximately 11 months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. The trial aims to provide valuable insights into the treatment of pulmonary hypertension, contributing to the advancement of therapeutic options for this condition.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of available data, further information on drug administration, dosing schedules, and participant compliance monitoring cannot be described. The trial documentation does not include any additional relevant information regarding the substances involved in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 3 study, indicating it is focused on confirming the effectiveness of the intervention, monitoring side effects, and collecting information that will allow the intervention to be used safely. The estimated recruitment start date is March 1, 2024, with an anticipated end date of January 31, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 3 trials typically involve comprehensive data collection and analysis to evaluate the intervention's impact on the disease. The trial will likely employ validated scales, laboratory tests, or patient-reported outcomes to measure efficacy at predetermined timepoints throughout the study duration. The results will contribute to determining the intervention's potential for broader clinical use.